Development of a Novel Anti-CD44 Variant 4 Monoclonal Antibody C44Mab-108 for Immunohistochemistry

CD44 has been known as a marker of tumor-initiating cells, and plays pro-tumorigenic functions in many cancers. The splicing variants play critical roles in the malignant progression of cancers by promoting stemness, cancer cell invasion or metastasis, and resistance to chemo- and radiotherapy. To understand each CD44 variant (CD44v) function is essential to know the property of cancers and the establishment of the therapy. However, the function of the variant 4-encoded region has not been elucidated. Therefore, specific monoclonal antibodies (mAbs) against variant 4 are indispensable for basic research, tumor diagnosis, and therapy. In this study, we established anti-CD44 variant 4 (CD44v4) mAbs by immunizing mice with a peptide containing the variant 4-encoded region. We next performed flow cytometry, western blotting, and immunohistochemistry to characterize them. One of the established clones (C44Mab-108; IgG1, kappa) reacted with CD44v3-10-overexpressed Chinese hamster ovary-K1 cells (CHO/CD44v3-10). The KD of C44Mab-108 for CHO/CD44 v3-10 was 3.4 × 10−7 M. In western blot analysis, C44Mab-108 detected CD44v3-10 in the lysate of CHO/CD44v3-10 cells. Furthermore, C44Mab-108 stained formalin-fixed paraffin-embedded (FFPE) oral squamous carcinoma tissues in immunohistochemistry. These results indicated that C44Mab-108 is useful to detect CD44v4 in immunohistochemistry using FFPE tissues.

[1]  J. Essex,et al.  Reducing affinity as a strategy to boost immunomodulatory antibody agonism , 2023, Nature.

[2]  T. Todo,et al.  Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma , 2022, Molecular therapy oncolytics.

[3]  Y. Kato,et al.  Development of a Novel Anti−CD44 Monoclonal Antibody for Multiple Applications against Esophageal Squamous Cell Carcinomas , 2022, International journal of molecular sciences.

[4]  Y. Kato,et al.  Roles of Podoplanin in Malignant Progression of Tumor , 2022, Cells.

[5]  A. Syahir,et al.  CD44: A Multifunctional Mediator of Cancer Progression , 2021, Biomolecules.

[6]  Y. Kato,et al.  Epitope Mapping of the Anti-CD44 Monoclonal Antibody (C44Mab-46) Using Alanine-Scanning Mutagenesis and Surface Plasmon Resonance. , 2021, Monoclonal antibodies in immunodiagnosis and immunotherapy.

[7]  F. Gao,et al.  The state of CD44 activation in cancer progression and therapeutic targeting , 2021, The FEBS journal.

[8]  Y. Kato,et al.  Development of a Novel Epitope Mapping System: RIEDL Insertion for Epitope Mapping Method. , 2021, Monoclonal antibodies in immunodiagnosis and immunotherapy.

[9]  Y. Kato,et al.  Epitope Mapping of the Anti-CD44 Monoclonal Antibody (C44Mab-46) Using the REMAP Method. , 2021, Monoclonal antibodies in immunodiagnosis and immunotherapy.

[10]  M. Kawada,et al.  A cancer-specific anti-podocalyxin monoclonal antibody (60-mG2a-f) exerts antitumor effects in mouse xenograft models of pancreatic carcinoma , 2020, Biochemistry and biophysics reports.

[11]  M. Ikeguchi,et al.  Moving toward generalizable NZ-1 labeling for 3D structure determination with optimized epitope tag insertion , 2020, bioRxiv.

[12]  H. Harada,et al.  A defucosylated anti-CD44 monoclonal antibody 5-mG2a-f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma , 2020, Oncology reports.

[13]  F. Roviello,et al.  O‐glycan truncation enhances cancer‐related functions of CD44 in gastric cancer , 2019, FEBS letters.

[14]  H. Harada,et al.  Establishment of a monoclonal antibody PMab-233 for immunohistochemical analysis against Tasmanian devil podoplanin , 2019, Biochemistry and biophysics reports.

[15]  S. Akashi,et al.  Application of the NZ‐1 Fab as a crystallization chaperone for PA tag‐inserted target proteins , 2019, Protein science : a publication of the Protein Society.

[16]  H. Harada,et al.  PMab-213: A Monoclonal Antibody for Immunohistochemical Analysis Against Pig Podoplanin. , 2019, Monoclonal antibodies in immunodiagnosis and immunotherapy.

[17]  T. Mizuno,et al.  PMab-210: A Monoclonal Antibody Against Pig Podoplanin. , 2019, Monoclonal antibodies in immunodiagnosis and immunotherapy.

[18]  H. Harada,et al.  PMab-219: A monoclonal antibody for the immunohistochemical analysis of horse podoplanin , 2019, Biochemistry and biophysics reports.

[19]  C. Chen,et al.  The biology and role of CD44 in cancer progression: therapeutic implications , 2018, Journal of Hematology & Oncology.

[20]  H. Harada,et al.  Anti-podocalyxin antibody exerts antitumor effects via antibody-dependent cellular cytotoxicity in mouse xenograft models of oral squamous cell carcinoma , 2018, Oncotarget.

[21]  Y. Kato,et al.  Detection of high CD44 expression in oral cancers using the novel monoclonal antibody, C44Mab-5 , 2018, Biochemistry and biophysics reports.

[22]  M. Fukayama,et al.  ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity. , 2017, Monoclonal antibodies in immunodiagnosis and immunotherapy.

[23]  M. Fukayama,et al.  Antitumor activity of chLpMab‐2, a human–mouse chimeric cancer‐specific antihuman podoplanin antibody, via antibody‐dependent cellular cytotoxicity , 2017, Cancer medicine.

[24]  M. Fukayama,et al.  Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity. , 2017, Monoclonal antibodies in immunodiagnosis and immunotherapy.

[25]  V. Orian-Rousseau,et al.  CD44: More than a mere stem cell marker. , 2016, The international journal of biochemistry & cell biology.

[26]  T. Nayak,et al.  First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors , 2016, Oncotarget.

[27]  Y. Kato,et al.  Establishment of Mouse Monoclonal Antibody LpMab-13 Against Human Podoplanin. , 2016, Monoclonal antibodies in immunodiagnosis and immunotherapy.

[28]  H. Kubo,et al.  Novel Monoclonal Antibody LpMab-17 Developed by CasMab Technology Distinguishes Human Podoplanin from Monkey Podoplanin. , 2016, Monoclonal antibodies in immunodiagnosis and immunotherapy.

[29]  J. Takagi,et al.  Tailored placement of a turn-forming PA tag into the structured domain of a protein to probe its conformational state , 2016, Journal of Cell Science.

[30]  P. Goichberg,et al.  LpMab-12 Established by CasMab Technology Specifically Detects Sialylated O-Glycan on Thr52 of Platelet Aggregation-Stimulating Domain of Human Podoplanin , 2016, PloS one.

[31]  Y. Kato,et al.  LpMab-19 Recognizes Sialylated O-Glycan on Thr76 of Human Podoplanin. , 2016, Monoclonal antibodies in immunodiagnosis and immunotherapy.

[32]  Y. Hozumi,et al.  Monoclonal Antibody LpMab-9 Recognizes O-glycosylated N-Terminus of Human Podoplanin. , 2015, Monoclonal antibodies in immunodiagnosis and immunotherapy.

[33]  M. Fukayama,et al.  The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity , 2015, Oncotarget.

[34]  D. Wei,et al.  Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target , 2015, Stem cells translational medicine.

[35]  Y. Kato,et al.  Characterization of Monoclonal Antibody LpMab-3 Recognizing Sialylated Glycopeptide of Podoplanin , 2015, Monoclonal antibodies in immunodiagnosis and immunotherapy.

[36]  Y. Kato,et al.  A Cancer-specific Monoclonal Antibody Recognizes the Aberrantly Glycosylated Podoplanin , 2014, Scientific Reports.

[37]  Junichi Takagi,et al.  PA tag: a versatile protein tagging system using a super high affinity antibody against a dodecapeptide derived from human podoplanin. , 2014, Protein expression and purification.

[38]  V. Orian-Rousseau,et al.  Perspectives of CD44 targeting therapies , 2014, Archives of Toxicology.

[39]  S. Okazaki,et al.  Redox regulation in stem-like cancer cells by CD44 variant isoforms , 2013, Oncogene.

[40]  Y. Sekido,et al.  A Novel Targeting Therapy of Malignant Mesothelioma Using Anti-Podoplanin Antibody , 2013, The Journal of Immunology.

[41]  I. Pastan,et al.  Recombinant anti‐podoplanin (NZ‐1) immunotoxin for the treatment of malignant brain tumors , 2013, International journal of cancer.

[42]  M. Fukayama,et al.  Chimeric anti‐podoplanin antibody suppresses tumor metastasis through neutralization and antibody‐dependent cellular cytotoxicity , 2012, Cancer science.

[43]  M. Zöller.  CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? , 2011, Nature Reviews Cancer.

[44]  M. Ohmura,et al.  CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. , 2011, Cancer cell.

[45]  S. Keir,et al.  Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. , 2010, Nuclear medicine and biology.

[46]  Masahiro Uchino,et al.  Nuclear β-catenin and CD44 upregulation characterize invasive cell populations in non-aggressive MCF-7 breast cancer cells , 2010, BMC Cancer.

[47]  H. Riechelmann,et al.  Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. , 2008, Oral oncology.

[48]  J. Price,et al.  Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2. , 2008, Hybridoma.

[49]  Ronit Vogt Sionov,et al.  Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. , 2008, Seminars in cancer biology.

[50]  Hiromi Ito,et al.  Molecular analysis of the pathophysiological binding of the platelet aggregation‐inducing factor podoplanin to the C‐type lectin‐like receptor CLEC‐2 , 2007, Cancer science.

[51]  P. Herrlich,et al.  Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. , 2006, Molecular biology of the cell.

[52]  R. Savani,et al.  Hyaluronan-mediated angiogenesis in vascular disease: uncovering RHAMM and CD44 receptor signaling pathways. , 2007, Matrix biology : journal of the International Society for Matrix Biology.

[53]  Alexander Staab,et al.  A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus , 2006, Clinical Cancer Research.

[54]  P. Herrlich,et al.  CD44: From adhesion molecules to signalling regulators , 2003, Nature Reviews Molecular Cell Biology.

[55]  J. Sleeman,et al.  CD44 is required for two consecutive steps in HGF/c-Met signaling. , 2002, Genes & development.

[56]  K. Bennett,et al.  CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor , 1995, The Journal of cell biology.

[57]  S. Fox,et al.  Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. , 1994, Cancer research.

[58]  Martin Hofmann,et al.  A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells , 1991, Cell.